Bridging Connections and Insights from Investment Conferences

Bridging Connections and Insights from Investment Conferences

By Punit Dhillon, CEO and President of OncoSec Medical Incorporated

After the conclusion of several conferences this past month, I’ve had time to reflect on key takeaways and principal trends emerging in the healthcare sector. Despite less than stellar market conditions, speakers at conferences (such as J.P. Morgan 2016 and Bio CEO) and ancillary events remained optimistic and highlighted important insights into the future of healthcare. After a busy schedule with non-stop meetings and presentations, I returned home confident in OncoSec’s place in the burgeoning cancer immunotherapy landscape.

Upon receiving Investigational Review Board (IRB) approval, OncoSec rolls out a Phase II clinical trial evaluating OncoSec’s electroporation therapy for the treatment of cutaneous T-cell lymphoma. The trial takes place at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

UCSF investigators actively recruit up to 27 patients with cutaneous T-cell lymphoma and administer the first doses of the immune-stimulating agent interleukin-12 (DNA IL-12) via electroporation. One treatment cycle consists of three treatments applied to up to four lesions on days one, five and eight, with a maximum dose of 3.0 mg DNA IL-12 per treatment cycle.

OncoSec is granted a new method of use patent from the Commissioner of Patents, Commonwealth of Australia Patent Office. The patent covers the company’s OMS (OncoSec Medical System) treatment platform as a “ Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection”.

The patent offers potential for OMS technology to be used to treat the margins of solid tumors following surgical resection, thereby expanding of OncoSec’s market opportunities considerably.

OncoSec enters into an exclusive cGMP manufacturing agreement with VGXI Inc. for the production of interleukin-12 plasmid DNA (DNA IL-12). VGXI possesses a patented DNA plasmid manufacturing process essential to the production of DNA IL-12.

OncoSec administers DNA IL-12 as part of an innovative immunotherapy for treating skin cancers. With large-scale process development and clinical manufacturing of this immunotherapeutic, OncoSec has the ability to scale up production for its OMS (OncoSec Medical System) treatment activities.

OncoSec releases Phase IV study data demonstrating that chemotherapy delivered by electroporation compares favorably to standard outcomes associated with surgery for patients with head and neck cancer.

The study demonstrates local tumor control in 94% of primary and 57% of recurrent tumors as well as enhanced quality of life for patients treated via electroporation using the OncoSec Medical System (OMS). Data is taken from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck, each of whom was treated with OMS in a European trial. In terms of both tumor control and overall quality of life, the OMS system compares favorably to surgical intervention.

OncoSec announces the closing of a sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering. Investors also receive warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

The gross proceeds of the offering are $7.75 million, with net proceeds of approximately $7.2 million.

Oncosec initiates two additional enrolling sites for its Phase II metastatic melanoma clinical trials.

Both the John Wayne Cancer Institute in Santa Monica, CA, and Lakeland Comprehensive Cancer Center in Lakeland, FL are initiated as trial sites, and investigators begin screening patients.

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma are enrolled in this Phase II, single-arm, open-label and multi-center study.

SAN DIEGO, CA, February 29, 2012 — OncoSecMedical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been featured in an editorial piece in the March issue of Medical Device & Diagnostic Industry outlining development of its technology platform for treatment of rare and deadly skin cancers.

The article titled “OncoSec Could Revolutionize Oncology Therapy,” details the company’s promising OMS ElectroOncology treatment platform, as well as the on-going Phase II clinical studies in metastatic melanoma and Merkel cell carcinoma. The article also notes the company’s upcoming milestones for 2012.

To read the article in its entirety, please visit the following link:
http://www.mddionline.com/article/oncoSec-could-revolutionize-oncology-therapy

Medical Device & Diagnostic Industry (MD&DI) is a monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnosticproducts. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. Readers are professional personnel in product R&D, design, manufacturing, quality assurance, regulatory affairs, and corporate management. Worldwide circulation is approximately 50,500.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

The first patient with metastatic melanoma is dosed during a Phase II clinical trial evaluating OncoSec’s OMS system.

After Investigational Review Board (IRB) approval is received by the University of California, San Francisco, UCSF investigators begin actively recruiting patients with stage III or IV cutaneous and in-transit metastatic melanoma for the trial. A total of up to 25 patients is enrolled in this Phase II, single-arm, open-label and multi-center study.

Physicians at the University of Washington and Seattle Cancer Care Alliance, in conjunction with the Fred Hutchinson Cancer Center, treat several patients in an open-label Phase II clinical trial evaluating OncoSec’s OMS electroporation therapy for the treatment of Merkel cell carcinoma.

The clinical trial is designed to test DNA IL-12 administered using OncoSec’s novel treatment approach for immunotherapy to patients with local and distant Merkel cell carcinoma. As many as 15 patients with local and distant Merkel cell carcinoma are enrolled in the trial.


1 2 3
Real Time Web Analytics